Cargando…

Cardiac arrest caused by nafamostat mesilate

A 65-year-old man was transferred from the Department of Vascular Surgery to Nephrology because of cardiac arrest during hemodialysis. He underwent incision and drainage for treatment of a buttock abscess. Nafamostat mesilate was used as an anticoagulant for hemodialysis to address bleeding from the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyo Shik, Lee, Kyung Eun, Oh, Ji Hyun, Jung, Chan Sung, Choi, Dughyun, Kim, Yunsuek, Jeon, Jin Seok, Han, Dong Cheol, Noh, Hyunjin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025458/ https://www.ncbi.nlm.nih.gov/pubmed/27668164 http://dx.doi.org/10.1016/j.krcp.2015.10.003

Ejemplares similares

Cardiac arrest caused by nafamostat mesilate: Kounis syndrome in the dialysis room?
por: Koniari, Ioanna, et al.
Publicado: (2017)

Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation
por: Han, Sang Jin, et al.
Publicado: (2011)

Utility and safety of nafamostat mesilate for anticoagulation in dogs
por: Isayama, Noriko, et al.
Publicado: (2022)

The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
por: Kim, Joo Seong, et al.
Publicado: (2022)

The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2022)

Validation of Nafamostat Mesilate as an Anticoagulant in Extracorporeal Membrane Oxygenation: A Large-Animal Experiment
por: Han, Sung Joon, et al.
Publicado: (2018)

Nafamostat Mesilate: Can It Be Used as a Conduit Preserving Agent in Coronary Artery Bypass Surgery?
por: Yoon, Yoo Sang, et al.
Publicado: (2013)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway
por: Choi, Sujeong, et al.
Publicado: (2016)

Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer
por: Uwagawa, Tadashi, et al.
Publicado: (2022)

Nafamostat Mesilate Inhibits TNF-α-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production
por: Kang, Min-Woong, et al.
Publicado: (2015)

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells
por: Sugano, Hiroshi, et al.
Publicado: (2018)

Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial
por: Choi, Ji-Young, et al.
Publicado: (2015)

The modulation of TRPM7 currents by nafamostat mesilate depends directly upon extracellular concentrations of divalent cations
por: Chen, Xuanmao, et al.
Publicado: (2010)

Ability of Nafamostat Mesilate to Prolong Filter Patency during Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Randomized Controlled Study
por: Lee, Yong Kyu, et al.
Publicado: (2014)

Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition
por: Chen, Tao, et al.
Publicado: (2014)

Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells
por: Takada, Naoki, et al.
Publicado: (2021)

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia
por: Ikeda, Mahoko, et al.
Publicado: (2023)

Cardiopulmonary arrest caused by nafamostat mesylate during hemodialysis
por: Shioya, Nobuki, et al.
Publicado: (2022)

Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis
por: Lin, Yao, et al.
Publicado: (2022)

Glycogen synthase kinase‐3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells
por: Haruki, Koichiro, et al.
Publicado: (2017)

Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials
por: Xie, Yu, et al.
Publicado: (2023)

Use of argatroban in combination with nafamostat mesilate in open-heart surgery for a pediatric patient with heparin-induced thrombocytopenia type II: a case report
por: Kawamoto, Shuji, et al.
Publicado: (2020)

Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis
por: Kim, Joo-Hee, et al.
Publicado: (2021)

Correction: Hiroshi Sugano et al. Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells. Cancers 2018, 10, 386
por: Sugano, Hiroshi, et al.
Publicado: (2019)

Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial
por: Hirota, Morihisa, et al.
Publicado: (2019)

Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020)

Acute eosinophilic pneumonia caused by camostat mesilate: The first case report
por: Ota, Shinichiro, et al.
Publicado: (2016)

The authors’ reply
por: Kim, Hyo Shik, et al.
Publicado: (2017)

Nafamostat for Prophylaxis against Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Compared with Gabexate
por: Chang, Jae Hyuck, et al.
Publicado: (2009)

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
por: Park, Yeon Hee, et al.
Publicado: (2017)

Crystal structure of nafamostat dimesylate
por: Fujii, Isao
Publicado: (2021)

Nafamostat: Hyperkalaemia: case report
Publicado: (2021)

Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis
por: Oh, Hyeon Seok, et al.
Publicado: (2022)

Pergolide Mesilate May Improve Fatigue in Patients with Parkinson’s Disease
por: Abe, Kazuo, et al.
Publicado: (2002)

Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach
por: Kim, Hyeon-A, et al.
Publicado: (2022)

Novel mutations in patients with X-linked Alport syndrome: Two case reports
por: Oh, Songhee, et al.
Publicado: (2019)

Impaired fasting glucose and development of chronic kidney disease in non-diabetic population: a Mendelian randomization study
por: Kim, Hyoungnae, et al.
Publicado: (2020)

Association between blood pressure and the risk of chronic kidney disease in treatment-naïve hypertensive patients
por: Lee, Haekyung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qte9j4dcm8mqcgjdkg5lh3ss89